Lay summary

The purpose of the study is to find out of the study drug PF-07321332 (nirmatrelvir) given with ritonavir, helps treat non-hospitalised symptomatic children with COVID-19 who are at risk of their COVID-19 infection getting worse.

Duration of study

34 days


Pfizer, INC

Population (age group)

Birth (postmenstrual age of 44 weeks or greater at the time of screening) to <18 years of age.